Overview
Chromagenics develops epigenomic liquid biopsy tests that detect early-stage cancers through methylation signatures in cell-free DNA from a standard blood draw.
More in Oncology Genomics
Latest industry news
Illumina and Lucence Selected to Power Singapore's National Genome Sequencing Project
2026-11-19 ยท Industry
Has the $100 Liquid Biopsy Arrived? AMP 2026 Puts Cost Breakthrough Under the Microscope
2026-11-18 ยท Research
FDA Approves Liquid Biopsy Companion Diagnostic for Breast Cancer Therapy, Expanding Non-Invasive Testing Frontier
2026-11-17 ยท Product
Regeneron Wins FDA Approval for First Neurosensory Gene Therapy, Marking a Landmark for Genomic Medicine
2026-11-16 ยท Product
Company details
Category
๐ฌ Oncology Genomics
Location
Boston, MA, USA
Funding
Series B โ $45M led by OrbiMed Advisors
Website
www.chromagenics.comListed
2026-11-16
Is this your company?
Claim this listing to add your logo, full description, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach genomics professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ